**THURSDAY, SEPTEMBER 26**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>12:00 noon</td>
<td>EXHIBIT SET-UP — WILSHIRE BALLROOM, SANTA MONICA SUITE</td>
</tr>
<tr>
<td>12:00 – 3:00 pm</td>
<td>EXECUTIVE COMMITTEE MEETING — BOARDROOM</td>
</tr>
<tr>
<td>4:00 – 7:00 pm</td>
<td>MEETING REGISTRATION — PRE-FUNCTION, BEVERLY HILLS BALLROOM</td>
</tr>
<tr>
<td>4:00 – 6:50 pm</td>
<td>Interesting Retinal Case Presentations/Videos — BEVERLY HILLS BALLROOM</td>
</tr>
<tr>
<td>7:00 – 10:00 pm</td>
<td>Welcoming Reception — AQUA STAR POOL</td>
</tr>
</tbody>
</table>

**FRIDAY, SEPTEMBER 27**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:00 am</td>
<td>MEETING REGISTRATION — PRE-FUNCTION, BEVERLY HILLS BALLROOM</td>
</tr>
<tr>
<td></td>
<td>CONTINENTAL BREAKFAST/EXHIBITS — WILSHIRE BALLROOM, SANTA MONICA SUITE</td>
</tr>
<tr>
<td>7:30 – 11:00 am</td>
<td>Accompanying Persons Hospitality Suite — STARDUST ROOM, 8TH FLOOR</td>
</tr>
<tr>
<td>8:00 am – 12:05 pm</td>
<td>Scientific Session — BEVERLY HILLS BALLROOM</td>
</tr>
<tr>
<td>10:00 am – 2:45 pm</td>
<td>Accompanying Persons Tours/Lunch</td>
</tr>
<tr>
<td>12:05 – 1:00 pm</td>
<td>Scientific Session Attendees Lunch — OASIS COURTYARD</td>
</tr>
<tr>
<td>1:00 – 2:00 pm</td>
<td>Poster Session/Dessert — BEVERLY HILLS BALLROOM FOYER</td>
</tr>
<tr>
<td>2:00 – 5:00 pm</td>
<td>Scientific Session — BEVERLY HILLS BALLROOM</td>
</tr>
<tr>
<td>7:00 – 10:00 pm</td>
<td>The Getty Center — Buses depart 6:30 pm</td>
</tr>
</tbody>
</table>

**SATURDAY, SEPTEMBER 28**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:00 am</td>
<td>MEETING REGISTRATION — PRE-FUNCTION, BEVERLY HILLS BALLROOM</td>
</tr>
<tr>
<td></td>
<td>CONTINENTAL BREAKFAST/EXHIBITS — WILSHIRE BALLROOM, SANTA MONICA SUITE</td>
</tr>
<tr>
<td>7:30 – 11:00 am</td>
<td>Accompanying Persons Hospitality Suite — STARDUST ROOM, 8TH FLOOR</td>
</tr>
<tr>
<td>8:00 – 11:22 am</td>
<td>Scientific Session — BEVERLY HILLS BALLROOM</td>
</tr>
<tr>
<td>10:15 am – 3:00 pm</td>
<td>INTRODUCTION OF GUESTS OF HONOR/ANNUAL BUSINESS MEETING — BEVERLY HILLS BALLROOM</td>
</tr>
<tr>
<td>11:22 am – 12:15 pm</td>
<td>Scientific Session Attendees Lunch — OASIS COURTYARD</td>
</tr>
<tr>
<td>12:15 – 1:15 pm</td>
<td>Scientific Session — BEVERLY HILLS BALLROOM</td>
</tr>
<tr>
<td>7:00 pm</td>
<td>Reception/Banquet — INTERNATIONAL BALLROOM</td>
</tr>
</tbody>
</table>

**SUNDAY, SEPTEMBER 29**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:30 am</td>
<td>MEETING REGISTRATION — PRE-FUNCTION, BEVERLY HILLS BALLROOM</td>
</tr>
<tr>
<td></td>
<td>CONTINENTAL BREAKFAST/EXHIBITS — WILSHIRE BALLROOM, SANTA MONICA SUITE</td>
</tr>
<tr>
<td>8:00 am – 12:14 pm</td>
<td>Scientific Session — BEVERLY HILLS BALLROOM</td>
</tr>
<tr>
<td></td>
<td>Adjourn</td>
</tr>
</tbody>
</table>
4:00 pm  One-Year-Old Girl with Seizures, Right-Sided Atrophy and Laminar Necrosis of the Brain, and New Onset Exotropia in the Left Eye
Szilárd Kiss, MD, New York, NY

4:05 pm  A Two-Year-Old Child with Bilateral Progressive Retinal Non-Perfusion
Prithvi Mruthyunjaya, MD, Durham, NC

4:10 pm  New Ocular Diagnostic Findings of a Case of Hurler Scheie Syndrome
Jiong Yan, MD, Atlanta, GA

4:15 pm  Bilateral Proliferative Retinopathy on a 13-Year-Old Afro-Brazilian Boy Without Sickle Cell Disease
Arnaldo Bordon, MD, Sao Paolo, Brazil

4:20 pm  Eyes, Lungs and Guts....
Audina Berrocal, MD, Miami, FL

4:25 pm  What Does the Abdomen Have to do With This Vision Loss?
Colin McCannel, MD, Los Angeles, CA

4:30 pm  Evolution of Sub-RPE Deposits Prior to the Diagnosis of Vitreoretinal and CNS Lymphoma
Peter Campbell, MD, Portland, OR

4:35 pm  Is That All There Is?
Jose Pulido, MD, Rochester, MN

4:40 pm  Bilateral, Multifocal Central Serous-like Chorioretinopathy due to MEK Inhibition for Metastatic Cutaneous Melanoma
Stephen Kim, MD, Nashville, TN

4:45 pm  Sudden Vision Loss in Pregnant Woman
Linda Lam, MD, Los Angeles, CA

4:50 pm  Planned Preterm Delivery and Treatment of an Infant with Norrie Disease
Robert Sisk, MD, Cincinnati, OH

4:55 pm  Purtscher’s Retinopathy After an Unusual Procedure
Dean Elliott, MD, Boston, MA

5:00 pm  Choroidal Ischemia
Edwin Ryan, MD, Minneapolis, MN

5:05 pm  Acute Visual Loss Associated with SubLM Hemorrhage Following Neurosurgical Intervention for Clipping of Unruptured Aneurysm Successfully Treated with YAG Laser Internal Limiting Membranotomy
Min Kim, MD, Seoul, S. Korea

5:10 pm  Poor Vision and Optic Atrophy Following Macular Surgery — a Histopathological Correlation
Billy Pan, MD, Burnsville, MN

5:15 pm  White Dots... Ever Challenging in Diagnosis and Management
Quan Dong Nguyen, MD, Baltimore, MD

5:20 pm  Go Away Spot!
James Lai, MD, Honolulu, HI

5:25 pm  Exudative Macular Detachment
Mark Johnson, MD, Ann Arbor, MI
5:30 pm  Central Serous Retinopathy 50 Years Follow Up: A Family History
  Felix Sabates, MD, Kansas City, MO
5:35  Flying High But Relapsing Vision Loss
  Tara McCannel, MD, Los Angeles, CA
5:40  Flickering Photopsias in Two Patients
  Johnny Tang, MD, Cleveland, OH
5:45  Sequential Bilateral Central Retinal Vein Occlusions in a Cystic Fibrosis
  Patient with Hyperhomocysteinemia and Hypergamma-Globulinemia
  Rony Gelman, MD, Los Angeles, CA
5:50  What To Do About this Migratory Retinal and Subretinal Infiltration
  Michael Jumper, MD, San Francisco, CA
5:55  New Optical Coherence Tomography Finding in Macular Edema
  Oh Kwon, MD, Seoul, S. Korea
6:00  Progressive Expansion of the Hyperautofluorescent Ring in a Cone-Rod
  Dystrophy Patient
  Luiz Lima, MD, San Paolo, Brazil
6:05  Choroidal Lesion of Unknown Etiology
  Roxana Fu, MD, Pittsburgh, PA
6:10  Mystery Macula
  Richard McDonald, MD, San Francisco, CA
6:15  Mystery Case
  David Sarraf, MD, Los Angeles, CA

6:20 pm  Myopic Retinopathy with Choroidal Neovascular Membrane, Retinal
  Detachment and a Pit of the Optic Disc: A Case Report
  Boris Bajaire, MD, Bogota, Colombia
6:25  I Think There is Something Wrong with the Optic Nerve
  John Payne, MD, W. Columbia, SC
6:30  A Humbling Case
  Lucy Young, MD, Boston, MA

VIDEO PROGRAM

6:35  Pick and Place Segmentation and Delamination for Adherent Diabetic
  Plaques
  Raymond Iezzi, MD, Rochester, MN
6:40  Submacular Pneumatic Displacement of Subretinal Hemorrhage
  Tamer Mahmoud, MD, Durham, NC
6:45  My First Patient Treated with Ocriplasmin (Jetrea)
  Michael Singer, MD, San Antonio, TX
6:50  Adjourn
FRIDAY | SCIENTIFIC SESSIONS

FRIDAY, SEPTEMBER 27

7:00 am REGISTRATION/CONTINENTAL BREAKFAST/EXHIBITS —
PRE-FUNCTION, BEVERLY HILLS BALLROOM

7:55 WELCOME: Charles Barr, MD, President

DIABETES AND RETINAL VASCULAR DISEASE

PRESIDING OFFICER: Susan Bressler, MD
MODERATOR: John Christoforidis, MD

8:00 am Safety Evaluation of Two or More Dexamethasone Intravitreal Implants for Treatment of Macular Edema Associated with Retinal Vein Occlusion (The SHASTA Study)
Pravin Dugel, MD

8:05 am Factors Affecting the Frequency of Intravitreal Aflibercept Injection (IAI) During the PRN Phase of the COPERNICUS and GALILEO Central Retinal Vein Occlusion Studies
Lloyd Clark, MD

8:10 am Retinal Vessel Caliber in Central Retinal Vein Occlusion Patients After Treatment with Ranibizumab in the CRUISE Study
Rishi Singh, MD

8:15 am Intravitreal Bevacizumab Treatment for Macular Edema in Central Retinal Vein Occlusion and Branch Retinal Vein Occlusion
Adiel Barak, MD

8:20 am Correlation of Fundus Autofluorescence with Spectral Domain Optical Coherence Tomography and Vision in Diabetic Macular Edema
Hyung Chan Kim, MD

8:25 am Practice Variations in Interpretation of Diabetic Retinopathy Screening Photographs
Donald Fong, MD

8:30 am Screening for Diabetic Retinopathy: Ophthalmologists Versus Computer Algorithm Versus Reading Center Grading
James Folk, MD

8:35 am Screening for Proliferative Diabetic Retinopathy with Teleophthalmology: An Economic Analysis
Christopher Brady, MD

8:40 am Effects of Intravitreal Ranibizumab on Retinal Hard Exudates in Patients from the RIDE and RISE Diabetic Macular Edema Trials
Michael Ip, MD

8:45 am Effects of Ranibizumab on Contrast Sensitivity in Patients with Diabetic Macular Edema in the RIDE and RISE Trials
Neil Bressler, MD

8:50 am Prophylactic Intraoperative Intravitreal Triamcinolone During Cataract Surgery to Prevent Diabetic Macular Edema Progression
Uday Desai, MD

8:55 am Effect of Intravitreal Ranibizumab Administration on Aqueous Levels of IL-8 and IL-6 in Patients with Diabetic Macular Edema
Diana Do, MD
9:24 am  Navigated Laser on Threshold Macular Thickness for the Treatment of Center-Involved Diabetic Macular Edema: 12 Month Results
William Freeman, MD

9:33 am  Photobiomodulation in the Treatment of Patients with Noncenter-Involving Diabetic Macular Edema
Johnny Tang, MD

9:42 am  The Course of Eyes with Vitrectomy Prior to Enrollment in a Randomized Trial Evaluating Ranibizumab Plus Prompt or Deferred Laser for Diabetic Macular Edema
Susan Bressler, MD

9:51 am  Reduction of Interleukin-8 and Platelet-Derived Growth Factor by Topical Ketorolac 0.45% in Patients with Diabetic Retinopathy
Stephen Kim, MD

10:00 – 10:30 REFRESHMENT BREAK/EXHIBITS

10:30 am  A Comparison of Variable Dosing of Intravitreal Pegaptanib and Laser Treatment in Patients with Proliferative Diabetic Retinopathy
Victor Gonzalez, MD

10:39 am  Comparative, Randomized, Double Blinded Study of the Use of Anti-VEGF in Patients with Vitreous Hemorrhage or Trational Retinal Detachment Secondary to Diabetic Retinopathy
Arnaldo Bordon, MD

10:48 am  One-Year Results from a Randomized Clinical Trial Evaluating Intravitreal Ranibizumab or Saline for Vitreous Hemorrhage from Proliferative Diabetic Retinopathy
James Kinyoun, MD

10:57 am  Effects of Human Umbilical Tissue-Derived Cells (hUTCs) on Retinal Vascular Leakage in the Streptozotocin (STZ) Diabetic Rat
Joan Miller, MD

11:06 am  Phase I/II, Open-Label, Study of Intravitreal Ranibizumab 0.5 mg or High Dose 1.0 mg, for Retinal Vein Occlusion with Refractory Macular Edema Previously Receiving Intravitreal Bevacizumab (RAVEN)
Thomas O’Hearn, MD

11:15 am  Effect of Alternate Ranibizumab Dosing Regimens on Visual and Anatomic Outcomes in Subjects with Retinal Vein Occlusion (RVO): The SHORE Study
Michael Singer, MD

11:24 am  FELLOWSHIP RESEARCH AWARD PRESENTATION
Introduction: TBA
Characterization of the Choroid-Scleral Junction and Suprachoroidal Layer in Healthy Subjects on Enhanced-Depth Imaging Optical Coherence Tomography
Glenn Yiu, MD
11:34 am 7TH ANNUAL J. DONALD M. GASS AWARD
INTRODUCTION: Kimberly Drenser, MD
Telemedicine for Infant Retinal Screening
Michael Trese, MD

12:05 pm LUNCH — OASIS COURTYARD
1:00 POSTER VIEWING/DESSERT — BEVERLY HILLS FOYER

INFECTION AND INFLAMMATION
PRESIDING OFFICER: Thomas Friberg, MD
MODERATOR: Brian Berger, MD
2:00 Retinitis Pigmentosa: More Evidence of an Inflammatory Component
Thomas Friberg, MD
2:05 Combined Vitrectomy with Gas Tamponade and Posterior Glaucoma Tube Placement in Management of Complicated Uveitic Glaucoma
Mitchel Opremcak, MD
2:10 12-Month Results of the SAVE Study—Sirolimus as Therapeutic Approach of UVEITIS: A Randomized Study to Assess the Safety and Bioactivity of Intravitreal and Subconjunctival Injections of Sirolimus in Patients with Non-Infectious Uveitis
Quan Dong Nguyen, MD
2:19 Chronic Retinal Necrosis: The Fourth Necrotizing Herpetic Retinopathy Syndrome
Mark Johnson, MD

2:28 pm Visual Outcomes in Uveitis with Angiographic Macular Leakage Treated with the Fluocinolone Acetonide Implant or Standard Treatment
Thomas Albini, MD
2:37 2013 Update on DRCR.net Topical Antigiotic Use and Endophthalmitis Rates with Intravitreal Drug Injections
Christina Flaxel, MD
2:46 The Role of Topical Antibiotic Prophylaxis to Prevent Endophthalmitis After Intravitreal Injection
Philip Storey, MD
2:55 pm Endophthalmitis is More Common After Intravitreal Injection or Ranibizumab than Bevacizumab
Christopher Riemann, MD
3:04 Presentation of Fungal Endophthalmitis Outbreak Following Intravitreal Injection of Triamcinolone Contaminated by a Compounding Pharmacy
Kent Small, MD
3:13 – 3:43 REFRESHMENT BREAK/EXHIBITS — SANTA MONICA SUITE/WILSHIRE BALLROOM
**FRIDAY | SCIENTIFIC SESSIONS**

**MACULAR DISEASE**

**PRESIDING OFFICER:** Jennifer Lim, MD  
**MODERATOR:** Robert Sisk, MD

3:43 pm  Investigation of Risk Alleles Associated with Choroidal Neovascularization in Ocular Histoplasmosis Syndrome  
Martin Wilkes, MD

3:48 pm  Anti-VEGF Therapy for Choroidal Neovascularization (CNV) Associated with High Myopia: Patient and Treatment Characteristics  
Homayoun Tabandeh, MD

3:57 pm  Visual and Anatomic Results of the Macula Society Photodynamic Therapy (PDT) for Central Serous Chorioretinopathy (CSC) Retrospective Study  
Jennifer Lim, MD

4:06 pm  The Clinical Course of Vitreofoveal Adhesion Management by Initial Observation  
Vishak John, MD

4:15 pm  Subfoveal Lucency and Recovery of Foveal Anatomy After Macular Hole Closure in the Phase III Trials and Ocriplasmin  
Francisco Folgar, MD

4:24 pm  Correlation of Anatomic Changes and Visual Acuity (VA) Response in Patients from the Microplasmin for Intravitreous Injection: Traction Release without Surgical Treatment (MIVI-TRUST) Clinical Program  
Kevin Blinder, MD

**SATURDAY, SEPTEMBER 28**

4:33 pm  A New SD-Optical Coherence Tomography Presentation of Acute Macular Neuroretinopathy: Paracentral Acute Middle Maculopathy  
David Sarraf, MD

4:42 pm  Creation of an In-House Pharmacy for a Multi-Specialty Ophthalmic Practice  
Robert Foster, MD

4:51 pm  Adjourn

**SATURDAY | SCIENTIFIC SESSIONS**

**IMAGING**

**PRESIDING OFFICER:** Jackson Coleman, MD  
**MODERATOR:** David Telander, MD

8:00 am  Outer Retina Analysis by Optical Coherence Tomography in Cone-Rod Dystrophy Patients  
Luiz Lima, MD

8:05 am  Comparison of the Area of Retina Imaged on Ultra Wide-Field Fluorescein Angiography Using the Optos P200Tx and the Heidelberg Spectralis  
Szilárd Kiss, MD

---

7:00 am  REGISTRATION/CONTINENTAL BREAKFAST/EXHIBITS – PRE-FUNCTION, BEVERLY HILLS BALLROOM

---

8:00 am  OUTER RETINA ANALYSIS BY OPTICAL COHERENCE TOMOGRAPHY IN CONE-ROD DYSTROPHIES
8:10 am Assessing Photoreceptor Structure of Macular Holes with Adaptive Optics Imaging
Judy Kim, MD

8:15 am Directional Optical Coherence Tomography Improves Visualization of Photoreceptor Bands
Brandon Lujan, MD

8:24 am Outer Retinal Tubulations in the Comparison of Age-Related Macular Degeneration Treatment Trials (CATT)
Glenn Jaffe, MD

8:32 am High-Speed Optical Coherence Tomography as a Reliable Adjuvant Tool to Grade Ocular Anerior Chamber Inflammation
Sunir Garg, MD

8:41 am Evaluation of Retinal and Choroidal Perfusion Using High Frequency Ultrasound Imaging
Jackson Coleman, MD

8:50 am Multimodal Imaging of Residual Silicone Oil Microspherules In Vivo: Optic Nerve, Retina and Vitreous
Yale Fisher, MD

9:00 am Fellow Eye Prophylactic Scleral Buckle Placement Following Pediatric Retinal Detachment
Prithvi Mruthyunjaya, MD

9:09 am Long-Term Safety and Efficacy of Bevacizumab for the Treatment of Pediatric Retinal and Choroidal Diseases
Audina Berrocal, MD

9:18 am Outcomes of Clear Corneal Endoscopic Vitrectomy for Vitreoretinal Complications Following Retinoblastoma Treatment
Thomas Lee, MD

9:27 am Flow Cytometry and Gene Rearrangement in the Diagnosis of Intraocular Lymphoma
Janet Davis, MD

9:36 am Treatment of Choroidal Melanoma with Combined Simultaneous Hyperthermia by Transpupillary Thermotherapy and ICG-based Photodynamic Therapy for Choroidal Melanoma
Peter Liggett, MD

9:45 am Intravitreal Pharmacologic Management of Complex Visually Compromising Radiation Retinopathy Status Post Successful 125-Iodine Brachytherapy Treatment for Posterior Uveal Melanoma
Timothy Murray, MD

9:54 am Association of Clinical Risk Factors to Time of Metastasis in Patients with Uveal Melanoma
Evangelos Gragoudas, MD

10:03 am Outcomes After Plaque with Vitrectomy and Silicone Oil for Choroidal Melanoma
Tara McCannel, MD
10:12 – 10:42 REFRESHMENT BREAK/EXHIBITS — SANTA MONICA SUITE/WILSHIRE BALLROOM

10:42 am RAYMOND R. MARGHERIO AWARD PRESENTATION

INTRODUCTION: tba
Effects of Apolipoprotein E Deficiency, High Fat Diet and Aging on Laser Induced Choroidal Neovascularization (CNV) and Bruch’s Membrane-Retinal Pigment Epithelium (RPE) Interface Morphology

Dimitra Skondra, MD

10:52 RETINA RESEARCH AWARD OF MERIT

CHARLES L. SCHEPENS LECTURE

INTRODUCTION: Glenn Jaffe, MD
New Views of Retinal Microanatomy to Transform Retinal Practice

Cynthia Toth, MD

11:22 INTRODUCTION OF GUESTS OF HONOR

Stephen Ryan, MD BY Pat Wilkinson, MD
Bradley Straatsma, MD BY Steven Schwartz, MD

ANNUAL BUSINESS MEETING

12:15 – 1:15 LUNCH — OASIS COURTYARD

Surgery I

MODERATOR: Colin McCannel, MD

1:15 pm One-Year Results of the Prospective Retinal and Optic Nerve Vitrectomy Evaluation (PROVE) Study: A Controlled Clinical Trial

Rohan Shah, MD

1:20 Open Angle Glaucoma Following Uncomplicated Pars Plana Vitrectomy. Results of the Pan American Collaborative Retina Study Group

Lihteh Wu, MD

1:25 The Efficiency of Silicone Oil Aspiration Across Gauges and Cannula Types

Colin McCannel, MD

1:30 Refractive Outcome After Combined ‘Micro-Incision’ Cataract Surgery and 23-Gauge Vitrectomy: Preliminary Results

Christiane Falkner-Radler, MD

1:35 Retinal Remodeling in the Posterior Pole Following Macular Hole Surgery

Gene Chen, MD

1:40 Visual and Anatomic Outcomes of Epiretinal Membrane Peeling After Previous Retinal Detachment Repair

Ninel Gregory, MD
### 1:45 pm

**Surgical Outcomes in Patients with Macular Pucker and Good Preoperative Visual Acuity After Small Gauge Vitrectomy and Membrane Peeling**  
*Alexander Melamud, MD*

**Epiretinal Membrane Peeling Following Uncomplicated Primary Retinal Detachment Repair**  
*Eric Weichel, MD*

**Two-Step Procedure to Remove Eperetinal Membrane on Central Macula**  
*Oh Kwon, MD*

**A Detailed Evaluation of Brilliant Blue G Dye in Chromovitrectomy**  
*Michel Farah, MD*

**Vitrectomy for Floaters: Prospective Efficacy Analysis and Retrospective Safety Profile**  
*Jerry Sebag, MD*

**Retained Lens Fragments After Cataract Surgery: Outcomes of Same-Day Versus Later Para Plana Vitrectomy**  
*Harry Flynn Jr, MD*

**Individualized Optical Coherence Tomography-Guided Facedown Posturing After Macular Hole Surgery: Minimizing Treatment Burden and Maximizing Outcomes**  
*Taiji Sakamoto, MD*

**Outer Retinal Folds After Retinal Reattachment Surgery**  
*Dean Elliott, MD*

### 2:57 pm

**Photoreceptor Autophagy After Retinal Detachment: The Switch from Survival to Death**  
*Nicholas Chinskey, MD*

**PIONEER 18-Month Vitreoretinal Intraoperative Optical Coherence Tomography Results: Utilization and Surgeon Feedback**  
*Justis Ehlers, MD*

### 3:06

**REFRESHMENT BREAK/EXHIBITS — SANTA MONICA SUITE/WILSHIRE BALLROOM**

**AGE-RELATED MACULAR DEGENERATION 1**

**PRESIDING OFFICER: Jeffrey Heier, MD**  
**MODERATOR: Deeba Husain, MD**

**Quantitative Optical Coherence Tomography Subanalysis of Eyes with Age-Related Macular Degeneration-Related Choroidal Neovascularization Switched to Aflibercept Therapy**  
*Linda Lam, MD*

**Treatment Extension and Visual Outcomes of Anti-VEGF Therapy with Ranibizumab or Aflibercept for Neovascular Age-Related Macular Degeneration (Nv-AMD)**  
*Michelle Carle, MD*

**Intraocular Pressure in Patients with Neovascular Age-Related Macular Degeneration (AMD) Switched to Aflibercept Injection After Prior Anti-VEGF Treatments**  
*Irene Rusu, MD*
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
</table>
| 4:00 pm | Initial Results from the ROLL Trial: Aflibercept for Patients with Recalcitrant PEDs Related to Wet Age-Related Macular Degeneration  
Brandon Busbee, MD |
| 4:05 | Vision and Optical Coherence Tomography Results at Six Months After Switching to Aflibercept for Patients on Prior Ranibizumab or Bevacizumab Treatment for Exudative Age-Related Macular Degeneration  
Clement Chan, MD |
| 4:14 | Systemic Safety of Intravitreal Anti-VEGF Therapy in Select Patient Populations  
David Boyer, MD |
| 4:23 | Preliminary Results of a Dose Escalating Study Evaluating the Safety and Efficacy of Implantation of an ECT Device Secreting Soluble VEGF Receptor for the Long-Term Treatment of Wet Age-Related Macular Degeneration  
Hugo Quiroz-Mercado, MD |
| 4:32 | HARBOR 2-Year Results Support Individualized Dosing in Patients with Wet Age-Related Macular Degeneration  
Nauman Chaudhry, MD |
| 4:41 | Visual Acuity Following Early, Persistent Fluid in Patients with Neovascular Age-Related Macular Degeneration: Subgroup Analyses of the VIEW 1 and VIEW 2 Studies  
Jeffrey Heier, MD |
| 4:50 pm | The Comparative Effect of Treatment in Eyes with RPE Elevation in the VIEW 1 and VIEW 2 Studies of Wet Age-Related Macular Degeneration Patients  
Jason Slakter, MD |
| 4:59 | Addition of PDT for the Treatment of Neovascular Age-Related Macular Degeneration Refractory to Anti-VEGF Agents  
Lawrence Chong, MD |
| 5:08 | Neovessel Morphology by ICG Predicts Response to Anti-VEGF Therapy in Eyes with Serous Pigment Epithelial Detachments in Age-Related Macular Degeneration  
Priyatham Mettu, MD |
| 5:17 | Macular Atrophy as the Strongest Correlate of 7-Year Vision Outcomes with Ranibizumab Therapy for Age-Related Macular Degeneration (SEVEN-UP Study)  
Robert Bhisitkul, MD |
| 5:26 | Correlation of Long-Term Visual Outcomes with Initial Lesion Composition in Eyes with Newly Diagnosed Neovascular Age-Related Macular Degeneration  
Bailey Freund, MD |
| 5:35 | Adjourn |
SUNDAY | SCIENTIFIC SESSIONS

SUNDAY, SEPTEMBER 29

7:30 am  REGISTRATION/CONTINENTAL BREAKFAST/EXHIBITS –
PRE-FUNCTION, BEVERLY HILLS BALLROOM

AGE-RELATED MACULAR DEGENERATION II

PRESDING OFFICER: Gregg Kokame, MD
MODERATOR: Bernard Doft, MD

8:00  Mechanism of Retinal Pigment Epithlium (RPE) Tear Formation Revealed by Spectral Domain Optic Coherence Tomography (SD-OCT)
Aaron Nagiel, MD

8:05  Disease Activity in Disciform Scar Due to Age-Related Macular Degeneration
Elias Reichel, MD

8:10  Periodontal Disease and Age-Related Macular Degeneration:
A New Association
Jorge Arroyo, MD

8:19  The Complete 6-Month Results: High-Dose (2.0 mg Ranibizumab) Continuous Monthly Treatment for Polypoidal Choroidal Vasculopathy with Exudation and/or Bleeding
Gregg Kokame, MD

8:28  Real-World Monitoring of Patients with Common Retinal Diseases Treated with Anti-VEGF Agents
Nancy Holekamp, MD

8:37 am  Injection Clinic: A Rapid, Efficient and Safe Approach to Dealing with the Oodles of Patients Requiring Frequent VEGF Inhibitor Injection
Bernard Doft, MD

8:46  Lutein/Zeaxanthin and Omega-e Fatty Acids for Age-Related Macular Degeneration. Results of the Age-Related Eye Disease Study 2 (AREDS2) Randomized Clinical Trial
Emily Chew, MD

8:55  Effects of Genetic and Epigenetic Risk Factors on Response to Ranibizumab in Exudative Age-Related Macular Degeneration
Stefano Piermarocchi, MD

9:04  The Role of Genetics in Response to Anti-VEGF Therapy for Wet Age-Related Macular Degeneration
Jaclyn Kovach, MD

9:13  Serological Analysis of Age-Related Macular Degeneration Patients and Their Response to Therapy
Lawrence Morse, MD

9:22  Intravitreal Autologous Bone Marrow-Derived CD34+ Stem Cell Therapy for Degenerative Macular Disease
Susanna Park, MD

9:31  Autophagy in the Retinal Pigment Epitheliun: Insights into Age-Related Macular Degeneration
David Zacks, MD

9:40  Penetration and Transportation of Intravitreal Bevacizumab and Ranibizumab into the Optic Nerve of the Fellow Eye
Sophie Bakri, MD
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:28</td>
<td>Rate of Retinal Detachment Following Small Gauge Pars Plana Vitrectomy</td>
<td>Robert Mittra, MD</td>
</tr>
<tr>
<td>10:33</td>
<td>Giant Retinal Tear (GRT) Detachments: Surgical Strategies and Outcomes</td>
<td>John Pitcher III, MD</td>
</tr>
<tr>
<td>10:38</td>
<td>Clinicopathologic Correlations of Foreign Body Response within Postoperative Perfluoro-n-octane for Retinal Detachment Repair</td>
<td>Eric Sigler, MD</td>
</tr>
<tr>
<td>10:43</td>
<td>Relapse of Retinal Detachment in Highly Myopic Eyes. Use of Large Inferior Buckle Instead of Heavy Internal Tamponades</td>
<td>Guido Ripandelli, MD</td>
</tr>
<tr>
<td>10:48</td>
<td>Oral Fluoroquinolones and the Incidence of Rhegmatogenous Retinal Detachment and Symptomatic Retinal Breaks: A Population-Based Study</td>
<td>Kapil Kapoor, MD</td>
</tr>
<tr>
<td>11:02</td>
<td>Effects of Isotretinoin for Treating and Preventing PVR</td>
<td>Richard Kaiser, MD</td>
</tr>
<tr>
<td>11:11</td>
<td>Intraocular Lens Rescue Via a Novel Scleral Fixation Technique</td>
<td>Jonathan Prenner, MD</td>
</tr>
<tr>
<td>11:20</td>
<td>Sutureless Office Based Scleral Buckling</td>
<td>Nikolas London, MD</td>
</tr>
<tr>
<td>11:29</td>
<td>Nadir Placed Buckle (NPB): A New Epimacular Scleral Buckle for Treatment of Retinal Detachments Associated with Macular Holes in Highly Myopic Eyes</td>
<td>Jose Pulido, MD</td>
</tr>
<tr>
<td>11:38</td>
<td>Endolaser Associated with Cystoid Macular Edema (CME) and Epiretinal Membrane (ERM) Formation Following Small Gauge Retinal Detachment (RD) Repair</td>
<td>Tanuj Banker, MD</td>
</tr>
<tr>
<td>11:47</td>
<td>Long-Term Comparison of Eye with Retained and Removed Silicone Oil</td>
<td>Charles Barr, MD</td>
</tr>
<tr>
<td>11:56</td>
<td>The Effects of Triamcinolone Acetoniode on Retrobulbar Anesthesia and Pain Control Following Vitreoretinal Surgery</td>
<td>Sonia Mehta, MD</td>
</tr>
<tr>
<td>12:05</td>
<td>Adjourn</td>
<td></td>
</tr>
</tbody>
</table>
Multimodal Imaging and Multifocal Electroretinography Reveal New Insights into Gass’ Type 1 Stargardt Disease
Robert Sisk, MD

Phase I, Masked, Placebo-Controlled, Single and Multiple Ascending Intravenous Dose Studies Evaluating Systemic and Ocular Safety, Tolerability, and Visual Acuity Effects of RN6G (PF-04382923) in Subjects with Dry, Age-Related Macular Degeneration (ARMD)
Brian Berger, MD

Efficacy of Aflibercept in Bevacizumab Treated but Persistently Active Neovascular Age-Related Macular Degeneration
Mouhammed Abuattieh, MD

VEGF Overexpression as Possible Molecular Mechanism of Induction of Vitreous Tachyphylaxis After Treatment with Bevacizumab and Ranibizumab
Ricardo Japiassu, MD

Permeability of Ranibizumab and Bevacizumab through the Polarized Retina Pigment Epithelial Cells
Hiroto Terasaki, MD

Epithelial Membrane Protein 2 (EMP2) Controls VEGF Expression in Retinal Pigment Epithelium (RPE)
David Telander, MD, PhD

Association of VEGFR1 Polymorphisms with Neovascular Age-Related Macular Degeneration
Ivana Kim, MD

Cost Comparison of Intravitreal Aflibercept with Bevacizumab and Ranibizumab for the Treatment of Wet Age-Related Macular Degeneration
Adeel Shaikh, MD

Intravitreal Bevacizumab and Ranibizumab Reduce Cutaneous Tensile Strength During Early Phases of Wound Healing
John Christoforidis, MD

Trends in Utilization of Retinal Imaging for Patients with Exudative Macular Degeneration and Macular Edema from 2001 to 2009
Eric Schneider, MD

Diabetes is a Decisive Factor in Preserving the Eyes from Untreated Endogenous Klebsiella Pneumoniae Endophthalmitis
Shwu-Jiuan Sheu, MD

Intravenous Drug Abuse Associated Endogenous Endophthalmitis in Boston
Deeba Husain, MD

Rhegmatogenous Retinal Detachment in Patients with Acute Syphilitic Panuveitis
Sara Haug, MD, PhD
POSTERS

POSTER 14  Evaluation of an Adhesive Biopolymer for the Treatment of Retinal Detachment  
Jean-Pierre Hubschman, MD

POSTER 15  BAP1 Hereditary Cancer Syndrome Update  
Colleen Cebulla, MD, PhD

POSTER 16  Intraocular Pharmacokinetics and Retinal Toxicity of Mycophenolic Acid in Rabbits  
Francisco Max Damico, MD

POSTER 17  Vitreous Cavity and Retina Epithelial Downgrowth in Enucleated Specimens and in Eyes with Visual Potential  
Aleksandra Rachitskaya, MD

POSTER 18  Long-Term Follow-Up of Retinopathy of Prematurity (ROP)  
William Tasman, MD

POSTER 19  Vascular Adhesion Protein-1 is Elevated with VEGF in the Serum of Diabetic Patients and is Produced by VEGF Stimulation in Experimental High-Glucose Conditions  
Kousuke Noda, MD

POSTER 20  Aflibercept for the Treatment of PolypoidalChoroidalVasculopathy  
Sabah Shah, MD
<table>
<thead>
<tr>
<th>EXHIBITORS BY NAME</th>
<th>EXHIBITORS BY BOOTH NUMBER</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>WILSHIRE BALLROOM (WB) AND SANTA MONICA SUITE (SMS)</strong></td>
<td><strong>WILSHIRE BALLROOM (WB) AND SANTA MONICA SUITE (SMS)</strong></td>
</tr>
<tr>
<td>AKORN PHARMACEUTICALS</td>
<td>GENENTECH – GOLD PATRON</td>
</tr>
<tr>
<td>17 – WB</td>
<td>1 – SMS</td>
</tr>
<tr>
<td>ALCION – GOLD PATRON</td>
<td>ALIMERA SCIENCES</td>
</tr>
<tr>
<td>18 &amp; 21 – WB</td>
<td>3 – SMS</td>
</tr>
<tr>
<td>ALIMERA SCIENCES</td>
<td>ALLERGAN – PATRON</td>
</tr>
<tr>
<td>3 – SMS</td>
<td>4 – SMS</td>
</tr>
<tr>
<td>ALLERGAN – PATRON</td>
<td>HEIDELBERG ENGINEERING</td>
</tr>
<tr>
<td>4 – SMS</td>
<td>5 – SMS</td>
</tr>
<tr>
<td>ARCTIC GROUP OF COMPANIES</td>
<td>REGENERON</td>
</tr>
<tr>
<td>26 – SMS</td>
<td>6 &amp; 7 – SMS</td>
</tr>
<tr>
<td>BAUSCH &amp; LOMB</td>
<td>SYNERGETICS</td>
</tr>
<tr>
<td>9 – WB</td>
<td>8 – WB</td>
</tr>
<tr>
<td>CARL ZEISS MEDITEC</td>
<td>BAUSCH &amp; LOMB</td>
</tr>
<tr>
<td>22 – WB</td>
<td>9 – WB</td>
</tr>
<tr>
<td>DUTCH OPHTHALMIC USA</td>
<td>SANTEN</td>
</tr>
<tr>
<td>23 – WB</td>
<td>10 – WB</td>
</tr>
<tr>
<td>ELSEVIER</td>
<td>OCULUS SURGICAL, INC</td>
</tr>
<tr>
<td>TABLE 2 – WB</td>
<td>11 – WB</td>
</tr>
<tr>
<td>GENENTECH – GOLD PATRON</td>
<td>INSIGHT INSTRUMENTS, INC.</td>
</tr>
<tr>
<td>1 – SMS</td>
<td>12 – WB</td>
</tr>
<tr>
<td>HEIDELBERG ENGINEERING</td>
<td>VISIONCARE OPHTHALMIC TECH., INC.</td>
</tr>
<tr>
<td>5 – SMS</td>
<td>13 – WB</td>
</tr>
<tr>
<td>INSIGHT INSTRUMENTS, INC.</td>
<td>SEQUENOM CENTER</td>
</tr>
<tr>
<td>12 – WB</td>
<td>14 – WB</td>
</tr>
<tr>
<td>L W &amp; W</td>
<td>WOLTERS</td>
</tr>
<tr>
<td>TABLE 1 – WB</td>
<td>15 – WB</td>
</tr>
<tr>
<td>OCULUS SURGICAL, INC</td>
<td>THROMBOGENICS</td>
</tr>
<tr>
<td>11 – WB</td>
<td>16 – WB</td>
</tr>
<tr>
<td>OPTOS, INC</td>
<td>AKORN PHARMACEUTICALS</td>
</tr>
<tr>
<td>19 – WB</td>
<td>17 – WB</td>
</tr>
<tr>
<td>OPTOVUE, INC</td>
<td>ALCION – GOLD PATRON</td>
</tr>
<tr>
<td>20 – WB</td>
<td>18 &amp; 21 – WB</td>
</tr>
<tr>
<td>QUANTEL MEDICAL</td>
<td>OPTOS, INC</td>
</tr>
<tr>
<td>24 – WB</td>
<td>19 – WB</td>
</tr>
<tr>
<td>REGENERON</td>
<td>OPTOVUE, INC</td>
</tr>
<tr>
<td>6 &amp; 7 – SMS</td>
<td>20 – WB</td>
</tr>
<tr>
<td>RETINA TODAY</td>
<td>CARL ZEISS MEDITEC</td>
</tr>
<tr>
<td>TABLE 4 – WB</td>
<td>22 – WB</td>
</tr>
<tr>
<td>RETINAL PHYSICIAN</td>
<td>DUTCH OPHTHALMIC USA</td>
</tr>
<tr>
<td>TABLE 3 – WB</td>
<td>23 – WB</td>
</tr>
<tr>
<td>SANTEN</td>
<td>QUANTEL MEDICAL</td>
</tr>
<tr>
<td>10 – WB</td>
<td>24 – WB</td>
</tr>
<tr>
<td>SEQUENOM CENTER</td>
<td>VALEANT OPHTHALMICS</td>
</tr>
<tr>
<td>14 – WB</td>
<td>25 – WB</td>
</tr>
<tr>
<td>SYNERGETICS</td>
<td>ARCTIC GROUP OF COMPANIES</td>
</tr>
<tr>
<td>8 – WB</td>
<td>26 – SMS</td>
</tr>
<tr>
<td>THROMBOGENICS</td>
<td>L W &amp; W</td>
</tr>
<tr>
<td>16 – WB</td>
<td>TABLE 1 – WB</td>
</tr>
<tr>
<td>TOPCON MEDICAL SYSTEMS</td>
<td>ELSEVIER</td>
</tr>
<tr>
<td>15 – WB</td>
<td>TABLE 2 – WB</td>
</tr>
<tr>
<td>VALEANT OPHTHALMICS</td>
<td>RETINAL PHYSICIAN</td>
</tr>
<tr>
<td>25 – WB</td>
<td>TABLE 3 – WB</td>
</tr>
<tr>
<td>VISIONCARE OPHTHALMIC TECH., INC.</td>
<td>RETINA TODAY</td>
</tr>
<tr>
<td>13 – WB</td>
<td>TABLE 4 – WB</td>
</tr>
</tbody>
</table>
Save the date

The Retina Society

The 47th Annual Scientific Meeting

Philadelphia, Pennsylvania

at the historic Union League
September 11 – 14, 2014